A Phase I Clinical Trial of the Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption

The purpose of this study is to evaluate the safety, tolerability, and efficacy of N-803, an IL-15 superagonist, with or without combination broadly neutralizing antibodies (bNAbs), to induce HIV-1 control during analytic treatment interruption (ATI).

DURATION: May 2021 - Ongoing

STUDY TYPE: HIV Treatment

PHASE: 1

DESIGN: Randomized, parallel assigned, open-label, interventional study

STATUS: Ongoing

ENROLLMENT: ≈46

POPULATION: People living with HIV, 18-65 years old

NUMBER OF SITES: 12

SITE LOCATIONS: US

NCT #: NCT04340596

RESULTS